Acumen Pharmaceuticals, Inc. (ABOS) — Analyst outlook / Analyst consensus target is. Based on 7 analyst ratings, the consensus is bullish — 7 Buy.
The consensus price target is $7.00, representing an upside of 161.2% from the current price $2.68.
Analysts estimate Earnings Per Share (EPS) of $-1.60 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.71 vs est $-1.60 (missed -6.6%). 2025: actual $-2.00 vs est $-2.05 (beat +2.3%). Analyst accuracy: 96%.
ABOS Stock — 12-Month Price Forecast
$7.00
▲ +161.19% Upside
Average Price Target
Based on 7 Wall Street analysts offering 12-month price targets for Acumen Pharmaceuticals, Inc., the price target is $7.00.
The average price target represents a +161.19% change from the last price of $2.68.
ABOS Analyst Ratings
Buy
Based on 7 analysts giving stock ratings to Acumen Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — ABOS
96%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.71
vs Est –$1.60
▼ 6.2% off
2025
Actual –$2.00
vs Est –$2.05
▲ 2.4% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — ABOS
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
